Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | 10% owner | June 29, 2021 | July 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LENZ Therapeutics, Inc.
Report date June 29, 2021 · Filed July 01, 2021
Jointly reported with Samsara BioCapital, L.P., AKKARAJU SRINIVAS
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 6,167,763 |
Reported balance
After 2021-06-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-06-29 · Conversion · Acquired 6,167,763 · Balance 6,167,763 F1: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 6,908,870 |
Reported balance
After 2021-06-29 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-06-29 · Conversion · Acquired 741,107 · Balance 6,908,870 F1: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 22,753 |
Reported balance
After 2021-06-29 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-06-29 · Conversion · Acquired 22,753 · Balance 22,753 F1: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F3: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 7,393,870 |
Reported balance
After 2021-06-29 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-06-29 · Purchase · Acquired 485,000 · Balance 7,393,870 F2: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 37,753 |
Reported balance
After 2021-06-29 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-06-29 · Purchase · Acquired 15,000 · Balance 37,753 F3: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fund | 0 |
Reported balance
After 2021-06-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-29 · Conversion · Disposed 15,000,000 · Balance 0 F1: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fund | 0 |
Reported balance
After 2021-06-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-29 · Conversion · Disposed 1,802,372 · Balance 0 F1: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fund | 0 |
Reported balance
After 2021-06-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-06-29 · Conversion · Disposed 55,336 · Balance 0 F1: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F3: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date.
F2: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.
F3: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 55,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · derivative · entry 8 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 22,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F3 · ownership.nature: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 1,802,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · derivative · entry 7 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 741,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 15,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · derivative · entry 6 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 6,167,763 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.exercise_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F1 · derivative.expiration_date: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 15,000 | $17.00 | $255,000.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 5 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 37,753 F3 · ownership.nature: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 485,000 | $17.00 | $8,245,000.00 |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 4 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 7,393,870 F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 22,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 3 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 22,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F3 · ownership.nature: Shares held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Each of 436 LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 741,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 6,908,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 21:39 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 6,167,763 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-044507 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner 436, L.P. · CIK 0001844560 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 6,167,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the redeemable convertible preferred stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a one-for-2.432 basis, and had no expiration date. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.